小剂量卡培他滨单药治疗高龄恶性肿瘤患者的疗效和安全性  

Efficacy and safety of low-dose capecitabine monotherapy in elderly patients with malignant tumors

作　　者：康马飞[1] 卜庆[1] 董翠梅[1] 骆梅青[1] 廖漓漓[1] 石援援[1] 涂江江[1] 

机构地区：[1]桂林医学院附属医院肿瘤内科,广西桂林541001

出　　处：《现代肿瘤医学》2014年第2期436-437,共2页Journal of Modern Oncology

摘　　要：目的:观察小剂量卡培他滨单药治疗高龄恶性肿瘤患者的疗效和不良反应。方法:67例高龄(75-84岁,中位年龄79岁)初治恶性肿瘤患者(结直肠癌15例,胃癌13例,喉癌9例,口腔癌8例,卵巢癌9例,胰腺癌8例,肝细胞癌5例),每次给予卡培他滨700mg/m2,每天2次,连用14天,休息1周,每21天重复,直到疾病进展为止。结果:PR 8例(结肠癌2例,胃癌3例,喉癌1例,卵巢癌1例,胰腺癌1例),SD 42例,PD 17例,总有效率(ORR)11.9%,肿瘤控制率(DCR)74.6%,中位肿瘤进展时间(mTTP)5.9个月,中位生存期(mS)9.2个月。不良反应有手-足综合征发生率9.0%,均为I-II度,I度/II度粒细胞减少9.0%,恶心7.5%,I度腹泻10.4%。结论:小剂量卡培他滨单药治疗高龄恶性肿瘤患者有较高肿瘤控制率,不良反应轻微。Objective：To observe the efficacy and side effects of low - dose capecitabine lnonotherapy in elderly patients with malignant tmnors. Methods：Sixty - seven elderly patients（froln 75 to 84 years old, median age 79 years old） with malignant tumors （15 cases of eoloreetal cancer, 13 cases of gastric carcinoma,9 cases of laryngoeareinoma, 8 cases of mouth cancer,9 cases of ovarian cancer,8 cases of pancreatic cancer,5 cases of hepatocellular cancer）were initial treated, capecitabine 700mg/m^2, oral, bid, on d1-14,then had a week rest, repeated every 21 days, until the disease progress. Results：There were 8 patients achieved partial response（PR） （2 cases of colorectal cancer,3 cases of gastric carcinoma,1 case of laryngocarcinoma,1 ease of ovarian cancer, 1 case of pancreatic cancer） ,42 patients achieved a stable disease （SD） , 17 patients were progress disease （PD）, overall response rate （ ORR ） was 11.9 % and the disease control rate（DCR） was 74.6% ,the median time to progression（mTTP） was 5.9 months and the median survival （mS） was 9.2 months. The adverse effects were grade Ⅰ/Ⅱ hand-foot syndrome （9.0%） ,grade Ⅰ/Ⅱ granuloeytopenia（9.0% ） ,nausea（7.5% ） and grade Ⅰ diarrhea（10.4% ）. Conclusion：There was a higher DCR and rain side effects in elderly patients with malignant tmnors treated by low - dose capecitabine.

关 键 词：恶性肿瘤 药物疗法 卡培他滨 高龄患者 

分 类 号：R730.53[医药卫生—肿瘤]